GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race. Strong trial data boosts AstraZeneca’s long-term revenue outlook. Shares of ...

The rate of new chronic obstructive pulmonary disease (COPD) cases decreased from 2001 to 2020, although the prevalence of COPD has increased.

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations, debilitating attacks that signal progression of the ...

Select your location to view local American Lung Association events and news near you.

Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron reported one hit and one miss in their phase 3 itepekimab program. Roche ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AstraZeneca (LSE:AZN) reported that its monoclonal ...

Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many ...

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by ...